

-2-

Applicants note that the Advisory Action, mailed July 2, 2003, incorrectly checked box (a) for the period to reply to expire three months from the mailing date of the final rejection. The final rejection was mailed on March 25, 2003, and Applicants filed an Amendment After Final by Certificate of Mailing procedure on May 27, 2003. May 25, 2003 was a Sunday, and May 26, 2003 was Memorial Day, a Federal holiday; thus Applicants' Amendment After Final was timely filed within two months from the date of the final Office Action. Accordingly, the Advisory Action should have checked box (b) for the period to reply to expire on the date of the Advisory Action, July 2, 2003 (MPEP § 706.07(f), 8th edition, February 2003 revision). Applicants request a one month extension of time from July 2, 2003 to August 2, 2003, as noted above.

Please amend the application as follows:

In the Claims

Please cancel Claim 15.

Please amend Claims 14, 17, 18 and 51-54.

- E,
14. (Twice Amended) A method of predicting impaired glucose tolerance in an individual, comprising the steps of:
- a) obtaining a nucleic acid sample from an individual;
 - b) determining the nucleotide present at nucleotide position 29 of exon 10 of a glycerol kinase gene comprising SEQ ID NO: 5,
- wherein presence of a guanine at said position is predictive of impaired glucose tolerance in the individual as compared with an individual having an adenosine at said position.
17. (Twice Amended) A method of predicting hyperglycerolemia in an individual, comprising the steps of:
- a) obtaining a nucleic acid sample from an individual;
 - b) determining the nucleotide present at nucleotide position 29 of exon 10 of a glycerol kinase gene comprising SEQ ID NO: 5,
- wherein presence of a guanine at said position is predictive of hyperglycerolemia in the individual as compared with an individual having an adenosine at said position.

-3-

18. (Twice Amended) A method of assisting in the prediction of cardiovascular disease in an individual, comprising the steps of:
- a) obtaining a nucleic acid sample from an individual;
 - b) determining the nucleotide present at nucleotide position 29 of exon 10 of a glycerol kinase gene comprising SEQ ID NO: 5, wherein presence of a guanine at said position is predictive of cardiovascular disease in the individual as compared with an individual having an adenosine at said position.
51. (Amended) A method of assisting in the prediction of impaired glucose tolerance in an individual, comprising the steps of:
- a) obtaining a nucleic acid sample from an individual;
 - b) determining the nucleotide present at nucleotide position 29 of exon 10 of a glycerol kinase gene comprising SEQ ID NO: 5, wherein presence of a guanine at said position is predictive of impaired glucose tolerance in the individual as compared with an individual having an adenosine at said position.
- E,
(ONT) 52. (Amended) A method of assisting in the prediction of type 2 diabetes mellitus in an individual, comprising the steps of:
- a) obtaining a nucleic acid sample from an individual;
 - b) determining the nucleotide present at nucleotide position 29 of exon 10 of a glycerol kinase gene comprising SEQ ID NO: 5, wherein presence of a guanine at said position is predictive of type 2 diabetes mellitus in the individual as compared with an individual having an adenosine at said position.
53. (Amended) A method of assisting in the prediction of hyperglycerolemia in an individual, comprising the steps of:
- a) obtaining a nucleic acid sample from an individual;
 - b) determining the nucleotide present at nucleotide position 29 of exon 10 of a glycerol kinase gene comprising SEQ ID NO: 5, wherein presence of a guanine at said position is predictive of hyperglycerolemia in the individual as compared with an individual having an adenosine at said position.
54. (Amended) A method of assisting in the prediction of diabetes mellitus in an individual, comprising the steps of: